Janet R. Wade

1.4k total citations
37 papers, 1.0k citations indexed

About

Janet R. Wade is a scholar working on Statistics and Probability, Oncology and Pharmacology. According to data from OpenAlex, Janet R. Wade has authored 37 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Statistics and Probability, 7 papers in Oncology and 6 papers in Pharmacology. Recurrent topics in Janet R. Wade's work include Statistical Methods in Clinical Trials (11 papers), Pharmacogenetics and Drug Metabolism (6 papers) and Analytical Methods in Pharmaceuticals (6 papers). Janet R. Wade is often cited by papers focused on Statistical Methods in Clinical Trials (11 papers), Pharmacogenetics and Drug Metabolism (6 papers) and Analytical Methods in Pharmaceuticals (6 papers). Janet R. Wade collaborates with scholars based in United States, United Kingdom and Sweden. Janet R. Wade's co-authors include E. Niclas Jonsson, M. O. Karlsson, Curtis G. Wiltse, Rik C. Schoemaker, Nancy C. Sambol, Armel Stockis, Eric Snoeck, Mats O. Karlsson, Andrew W. Kelman and B. Whiting and has published in prestigious journals such as Antimicrobial Agents and Chemotherapy, The American Journal of Gastroenterology and Pharmaceutical Research.

In The Last Decade

Janet R. Wade

37 papers receiving 976 citations

Peers

Countries citing papers authored by Janet R. Wade

Since Specialization

Citations

This map shows the geographic impact of Janet R. Wade's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Janet R. Wade with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Janet R. Wade more than expected).

Fields of papers citing papers by Janet R. Wade

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Janet R. Wade. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Janet R. Wade. The network helps show where Janet R. Wade may publish in the future.

Co-authorship network of co-authors of Janet R. Wade

This figure shows the co-authorship network connecting the top 25 collaborators of Janet R. Wade. A scholar is included among the top collaborators of Janet R. Wade based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Janet R. Wade. Janet R. Wade is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Covariate modeling in pharmacometrics: General points for consideration 2024 ·CPT Pharmacometrics & Systems Pharmacology ·Kinjal Sanghavi, Jakob Ribbing, James A. Rogers, (unknown), Mats O. Karlsson, Nicholas H. G. Holford, (unknown), Malidi Ahamadi, Kenneth G. Kowalski, Susan Cole, Essam Ghazaly, Janet R. Wade, Chao Liu, Yaning Wang, Mirjam N. Trame, Hao Zhu, Justin Wilkins	22
2	Characterization of exposure–response relationships of ipatasertib in patients with metastatic castration-resistant prostate cancer in the IPATential150 study 2022 ·Cancer Chemotherapy and Pharmacology ·Naoki Kotani, Justin Wilkins, Janet R. Wade, (unknown), Dhruvitkumar S. Sutaria, Kenta Yoshida, (unknown), (unknown), Josep Garcia, Heather Hinton, Rucha Sane, Pascal Chanu	4
3	Population pharmacokinetics and covariate analysis of Sym004, an antibody mixture against the epidermal growth factor receptor, in subjects with metastatic colorectal cancer and other solid tumors 2019 ·Journal of Pharmacokinetics and Pharmacodynamics ·(unknown), Rik C. Schoemaker, (unknown), (unknown), Clara Montagut, Scott Kopetz, Josep Tabernero, Michael Kragh, Janet R. Wade	3
4	Evaluation of brivaracetam efficacy as monotherapy in adult patients with focal seizures 2017 ·Epilepsy Research ·Rik C. Schoemaker, Janet R. Wade, Joseph D’Souza, Armel Stockis	12
5	Brivaracetam population pharmacokinetics in children with epilepsy aged 1 month to 16 years 2017 ·European Journal of Clinical Pharmacology ·Rik C. Schoemaker, Janet R. Wade, Armel Stockis	30
6	Pharmacokinetics and Pharmacodynamics of the Non-Nucleoside Reverse-Transcriptase Inhibitor Etravirine in Treatment-Experienced HIV-1-Infected Patients 2010 ·Clinical Pharmacology & Therapeutics ·Thomas N. Kakuda, Janet R. Wade, Eric Snoeck, Peter Vis, Monika Schöller‐Gyüre, Monika Peeters, Chris Corbett, Steven Nijs, Johan Vingerhoets, Lorant Leopold, Goedele De Smedt, Brian Woodfall, Richard M. W. Hoetelmans	37
7	Basic PK/PD principles of drug effects in circular/proliferative systems for disease modelling 2010 ·Journal of Pharmacokinetics and Pharmacodynamics ·Philippe Jacqmin, Lynn McFadyen, Janet R. Wade	14
8	A receptor theory‐based semimechanistic PD model for the CCR5 noncompetitive antagonist maraviroc 2008 ·British Journal of Clinical Pharmacology ·Philippe Jacqmin, Lynn McFadyen, Janet R. Wade	10
9	Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa‐2a (40KD) plus ribavirin 2006 ·British Journal of Clinical Pharmacology ·Eric Snoeck, Janet R. Wade, Franck Le Duff, Matthew W. Lamb, Karin Jorga	69
10	Pharmacokinetics of ribavirin in patients with hepatitis C virus 2006 ·British Journal of Clinical Pharmacology ·Janet R. Wade, Eric Snoeck, Franck Le Duff, Matthew W. Lamb, Karin Jorga	44
11	A guide for reporting the results of population pharmacokinetic analyses: A Swedish perspective 2005 ·The AAPS Journal ·Janet R. Wade, (unknown), Tomas Salmonson	37
12	Nonlinearity detection: Advantages of nonlinear mixed-effects modeling 2000 ·PubMed ·E. Niclas Jonsson, M. O. Karlsson, Janet R. Wade	39
13	The population pharmacokinetics of recombinant‐ and urinary‐human follicle stimulating hormone in women 1998 ·British Journal of Clinical Pharmacology ·(unknown), Janet R. Wade, Ernest Loumaye, Alain Munafo	17
14	Assumption Testing in Population Pharmacokinetic Models: Illustrated with an Analysis of Moxonidine Data from Congestive Heart Failure Patients 1998 ·Journal of Pharmacokinetics and Biopharmaceutics ·M. O. Karlsson, E. Niclas Jonsson, Curtis G. Wiltse, Janet R. Wade	124
15	Discrimination between rival dosing histories. 1997 ·Pharmaceutical Research ·E. Niclas Jonsson, Janet R. Wade, Gun Almqvist, (unknown)	15
16	A population model for the follicular growth in women treated with follicle stimulating hormone 1997 ·Clinical Pharmacology & Therapeutics ·(unknown), Janet R. Wade, Ernest Loumaye, Alain Munafo	8
17	Interaction between structural, statistical, and covariate models in population pharmacokinetic analysis 1994 ·Journal of Pharmacokinetics and Biopharmaceutics ·Janet R. Wade, Stuart L. Beal, Nancy C. Sambol	55
18	Effect of misspecification of the absorption process on subsequent parameter estimation in population analysis 1993 ·Journal of Pharmacokinetics and Biopharmaceutics ·Janet R. Wade, Andrew W. Kelman, Catherine A. Howie, B. Whiting	58
19	A Novel Statistical Approach for the Comparison of Analytical Methods to Measure Angiotensin Converting Enzyme Activity, Enalaprilat, and Benazeprilat 1993 ·Journal of Pharmaceutical Sciences ·Janet R. Wade, (unknown), Andrew W. Kelman, Catherine A. Howie, Peter Meredith	5
20	Variability in the pharmacokinetics of epirubicin: a population analysis 1992 ·Cancer Chemotherapy and Pharmacology ·Janet R. Wade, Andrew W. Kelman, David Kerr, Jacques Robert, B. Whiting	46

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact